Evidence map›Paper›PMID 42412369›Full record

ArticleDermatology and therapy2026

Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study.

Manuel P Pereira, Pascale Salameh, Athanasios Tsianakas, Hermann Szymczak, Christian Apfelbacher, Sonja Ständer, Claudia Zeidler

Abstract read
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manuel P PereiraInstitute of Allergology, Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Allergology, Berlin, Germany.ORCID http://orcid.org/0009-0008-0162-0742
Pascale SalamehInstitute of Allergology, Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Allergology, Berlin, Germany.ORCID http://orcid.org/0000-0002-4780-0772
Athanasios TsianakasDepartment of Dermatology, Fachklinik Bad Bentheim, Bad Bentheim, Germany.ORCID http://orcid.org/0000-0003-1563-7402
Hermann SzymczakInstitute of Social Medicine and Health Systems Research, Medical Faculty, Otto Von Guericke University Magdeburg, Magdeburg, Germany.ORCID http://orcid.org/0000-0002-5550-3110
Christian ApfelbacherInstitute of Social Medicine and Health Systems Research, Medical Faculty, Otto Von Guericke University Magdeburg, Magdeburg, Germany.ORCID http://orcid.org/0000-0003-3805-8219
Sonja StänderDepartment of Dermatology, Section Pruritus Medicine and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany. Sonja.Staender@ukmuenster.de.ORCID http://orcid.org/0000-0003-3612-7786
Claudia ZeidlerDepartment of Dermatology, Section Pruritus Medicine and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.ORCID http://orcid.org/0000-0002-9485-8627

Funding

Novartis Pharma unrestricted grant
6 · The paper itself

Abstract

introductionChronic inflammatory skin conditions significantly impact the quality of life (QoL) of those affected. Itch is a cardinal symptom in many of these conditions, contributing decisively to the burden of disease. This cross-sectional study explored how itch and related factors mediate the relationship between disease severity and QoL impairment.

methodsAdult patients with chronic pruritus arising from psoriasis, atopic dermatitis, chronic prurigo, or chronic urticaria completed a set of validated questionnaires assessing worst and average itch intensity (worst itch intensity on the numerical rating scale [WI-NRS]/average itch intensity on the numerical rating scale [AI-NRS]), impairment of QoL with the 5-pruritus life quality (5PLQ), daily time with itch, scratching frequency, and sleep disturbance. Disease severity was evaluated using validated disease-specific scales. Spearman's rank correlation was performed to assess intercorrelations between 5PLQ scores, disease severity, and itch-related factors. A linear regression analysis investigated associations of 5PLQ with demographic and clinical factors. Mediation analyses examined whether the link between disease severity and 5PLQ scores was mediated by itch intensity, daily itch duration, scratching frequency, and sleep disturbance.

resultsA total of 522 patients (282 female, median age: 56.0 years) participated in the study. 5PLQ scores correlated weakly with disease severity (r = 0.201, p < 0.001), and strongly with itch-related factors (r = 515-0.603, p < 0.001). The linear regression analysis revealed a positive association between 5PLQ scores and female sex (β: 0.887, p = 0.003), moderate disease severity (β: 1.552, p = 0.032), scratching frequency (β: 0.370, p < 0.001), and sleep disturbance (β: 0.427, p < 0.001). Mediation analyses showed that the association between disease severity and QoL impairment was partially mediated by average itch intensity (indirect β: 0.168, p = 0.049), daily itch duration (indirect β: 0.270, p < 0.001), scratching frequency (indirect β: 0.205, p = 0.010), and sleep disturbance (indirect β: 0.235, p = 0.006).

conclusionsAverage itch intensity, daily itch duration, scratching, and sleep disturbance mediate the relationship between disease severity and impairment of QoL. Interventions targeting these aspects of disease may improve patient outcomes.

Indexed as

Atopic dermatitisChronic prurigoChronic pruritusItchMediation analysisPatient-reported outcome measuresPsoriasisQuality of lifeSleepUrticaria

Identifiers

PMID42412369
PMCPMC13558505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.